OPUS-TIMI 16 evaluated if an oral GP IIb/IIIa inhibitor, orbofiban, reduces major cardiovascular events for the treatment of patients with an unstable coronary syndrome within 72 hours. MAIN RESULTS:Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trialCirculation. 2000 Jul 11;102(2):149-56. PRESENTATIONS TIMI 16 Slides OTHER PUBLICATIONS Increased platelet reactivity … Continue reading OPUS-TIMI 16